ERK5 is required for pro-tumour macrophage activation (original) (raw)

S105 (LVSI +). In samples of benign tumor in 2 of 3 expression of survivin was not determined, and one was 0.015. In CTCs, isolated from peripheral blood of breast cancer patients, all 26 samples as determined by the gene expression of survivin with an average value (M±m) 0.90±0.19 (min 0.26; max 3.90). The level of expression of the control samples did not exceed 0.003. It should be noted that the maximum volume of expression obtained in samples of tumor patients with stage N +, and especially M1, on TNM classification. Any legitimate expression of survivin, depending on the size of the tumor had been received. In patients, receiving chemotherapy observed average expression of survivin gene, but never approached the indicators of control. Conclusions: Determination of expression of the gene survivin in primary tumor and the CTCs may be treated to one of the most promising markers of tumor progression and monitoring of breast cancer therapy. No conflict of interest. 485 WWP2 controls endothelial permeability by regulating the RAP1-RADIL signaling pathway